Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
See more from Benzinga
Senate Finance Committee Probe Reveals How AbbVie Exploits Offshore Subsidiaries To Avoid Tax Bills
FDA's Recommendation Before Clovis Submits Rubraca Application For Ovarian Cancer
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.